Antisoma: AS1404 improves PSA responses in prostate cancer

By E. Janene Geiss

Philadelphia, Sept. 18 - Antisoma plc said findings from its ongoing phase 2 trial of AS1404 in hormone-refractory prostate cancer show a markedly higher rate of PSA responses among men receiving AS1404.

Preliminary data from the first 64 of 74 patients in the trial show a PSA response rate of 57% in those receiving AS1404 plus docetaxel chemotherapy compared with 35% in those receiving docetaxel alone, according to a news release from the London biopharmaceutical company.

In addition, the proportion of men showing disease progression by PSA was almost halved in the AS1404 group, 17% versus 29% with docetaxel alone. The findings were presented Sunday at the Tumor Microenvironment meeting in Boston.

PSA is a protein, prostate-specific antigen. Levels of PSA in the blood are used in the diagnosis of prostate cancer and the tracking of responses to its treatment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.